0NZT.LSE UCB SA
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.44%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0NZT.LSE undervalued?
Graham numberThe Graham number of UCB SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
UCB SA fundamental analysis
No fundamental analysis for UCB SA yet.
UCB SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs …
Full company profileUCB SA financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
UCB SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 4.15B | 4.53B | 4.63B | 4.91B | 5.35B | - | - | - |
| Gross Profit | 2.95B | 3.33B | 3.43B | 3.65B | 3.98B | - | - | - |
| Operating Income | 855M | 1.09B | 1.11B | 1.07B | 971M | - | - | - |
| Net Income | 520M | 753M | 800M | 791M | 732M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 10.2B | 9.92B | 10.5B | 11.1B | 13.3B | - | - | - |
| Total Liabilities | 4.63B | 4.10B | 4.20B | 4.04B | 6.05B | - | - | - |
| Shareholders' Equity | 5.58B | 5.81B | 6.31B | 7.04B | 7.27B | - | - | - |
| Cash & Short-term Investments | 799M | 1.11B | 1.36B | 1.43B | 1.52B | - | - | - |
| Total Debt | 1.57B | 1.53B | 1.35B | 975M | 2.32B | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 427M | 927M | 1.09B | 882M | 1.08B | 1.55B | 1.12B | - |
| Capital Expenditure | 138M | 209M | 94.0M | 99.0M | 256M | 282M | 252M | - |
| Ratios | ||||||||
| ROE | 9.3% | 13.0% | 12.7% | 11.2% | 10.1% | - | - | - |
| ROA | 5.1% | 7.6% | 7.6% | 7.1% | 5.5% | - | - | - |
| Net Profit Margin | 12.5% | 16.6% | 17.3% | 16.1% | 13.7% | - | - | - |
| Debt to Equity | 0.28x | 0.26x | 0.21x | 0.14x | 0.32x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
UCB SA dividends
UCB SA has not paid dividends in the last 9 fiscal years.
Who owns UCB SA
- Insiders 36.28%
- Institutions 39.57%
- Public & others 24.16%
- Free float 120M
UCB SA company profile
- Company name
- UCB SA
- Ticker
- 0NZT.LSE
- ISIN
- BE0003739530
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 9,000
- Fiscal year end
- December
- Address
- Allée de la Recherche, 60, Brussels, Belgium, 1070
- Phone
- 32 2 559 99 99
- Website
- ucb.com
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
UCB SA management
10- Dr. Jean-Christophe TellierCEO & Executive Director · born 1959
- Ms. Sandrine Dufour CFAExecutive VP & CFO · born 1966
- Mr. Alistair HenryExecutive VP & Chief Scientific Officer · born 1967
- Ms. Denelle J. Waynick Johnson J.D.Executive VP & General Counsel · born 1967
- Mr. Jean-Luc FleurialExecutive VP & Chief Human Resources Officer · born 1965
- Mr. Emmanuel CaeymaexExecutive VP & Head of Patient Evidence · born 1969
- Ms. Fiona Du MonceauExecutive VP of Patient Impact & Chief Commercial Officer · born 1978
- Ms. Caroline VancoillieChief Accounting Officer & Head of Group Finance
- Gwendoline OrniggHead of Global Corporate Communication
- Veronique ToullyHead of Sustainability, Corporate Affairs & Enterprise Risk Management